UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended June 30, 2021

 

Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from  ________ to __________

 

Commission File Number: 001-38543

 

OptimizeRx Corporation

(Exact name of registrant as specified in its charter)

 

Nevada   26-1265381
(State or other jurisdiction of
incorporation or organization)
  (IRS Employer
Identification No.)

 

400 Water Street, Suite 200

Rochester, MI, 48307

(Address of principal executive offices)

 

248-651-6568

(Registrant's telephone number)

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days  Yes    No  

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes    No  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “small reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes    No  

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 17,618,607 common shares as of July 30, 2021.

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class   Trading symbol   Name of each exchange on which
registered
Common Stock   OPRX   Nasdaq Capital Market

  

 

 

 

 

 

TABLE OF CONTENTS

 

    Page 
     
  PART I – FINANCIAL INFORMATION  
     
Item 1: Financial Statements (unaudited)
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 13
Item 3: Quantitative and Qualitative Disclosures About Market Risk 17
Item 4: Controls and Procedures 18
     
  PART II – OTHER INFORMATION  
     
Item 1: Legal Proceedings 19
Item 1A: Risk Factors 19
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 19
Item 3: Defaults Upon Senior Securities 20
Item 4: Mine Safety Disclosure 20
Item 5: Other Information 20
Item 6: Exhibits 20

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Our condensed consolidated financial statements included in this Form 10-Q are as follows:

 

 

Page

Number

Condensed Consolidated Balance Sheets as of June 30, 2021 (unaudited) and December 31, 2020 (unaudited); 2
Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2021 and 2020 (unaudited); 3
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2021 (unaudited) 4
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2020 (unaudited) 5
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2021 and 2020 (unaudited); 6
Notes to Condensed Consolidated Financial Statements (unaudited). 7

 

1

 

 

OPTIMIZERx CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

  

    June 30,
2021
    December 31,
2020
 
             
ASSETS            
Current Assets            
Cash and cash equivalents   $ 83,923,455     $ 10,516,776  
Accounts receivable, net     17,933,926       17,885,705  
Prepaid expenses     3,124,479       4,456,611  
Total Current Assets     104,981,860       32,859,092  
Property and equipment, net     137,813       148,854  
Other Assets                
Goodwill     14,740,031       14,740,031  
Technology assets, net     4,896,016       5,251,822  
Patent rights, net     2,258,542       2,349,570  
Other intangible assets, net     4,203,777       4,519,552  
Right of use assets, net     392,482       445,974  
Other assets and deposits     12,859       12,859  
Total Other Assets     26,503,707       27,319,808  
TOTAL ASSETS   $ 131,623,380     $ 60,327,754  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Current Liabilities                
Accounts payable – trade   $ 805,461     $ 618,250  
Accrued expenses     2,088,651       2,420,361  
Revenue share payable     3,341,312       4,969,868  
Current portion of lease obligations     110,271       123,220  
Current portion of contingent purchase price payable     -       1,610,813  
Deferred revenue     319,609       285,795  
Total Current Liabilities     6,665,304       10,028,307  
Non-current Liabilities                
Lease obligations, net of current portion     282,934       325,533  
Total Non-current Liabilities     282,934       325,533  
Total Liabilities     6,948,238       10,353,840  
Commitments and contingencies (See Note 8)    
-
     
-
 
Stockholders’ Equity                
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no issued and outstanding at June 30, 2021 or December 31, 2020    
-
     
-
 
Common stock, $0.001 par value, 500,000,000 shares authorized, 17,495,429 and 15,223,340 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively     17,495       15,223  
Additional paid-in-capital     160,574,661       85,590,428  
Accumulated deficit     (35,917,014 )     (35,631,737 )
Total Stockholders’ Equity     124,675,142       49,973,914  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 131,623,380     $ 60,327,754  

 

The accompanying notes are an integral part of these condensed consolidated financial statements. 

 

2

 

 

OPTIMIZERx CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

    For the Three Months
Ended
    For the Six Months
Ended
 
    June 30,     June 30,  
    2021     2020     2021     2020  
                         
NET REVENUE   $ 13,625,639     $ 8,783,230     $ 24,854,850     $ 16,367,832  
COST OF REVENUES     5,580,964       3,639,016       10,685,567       6,880,779  
GROSS MARGIN     8,044,675       5,144,214       14,169,283       9,487,053  
                                 
OPERATING EXPENSES     7,704,536       6,200,027       14,467,452       12,802,118  
INCOME (LOSS) FROM OPERATIONS     340,139       (1,055,813 )     (298,169 )     (3,315,065 )
                                 
OTHER INCOME (EXPENSE)                                
Interest income     11,961       8,345       12,892       63,666  
Change in Fair Value of Contingent Consideration     -       (30,000 )     -       (30,000 )
                                 
TOTAL OTHER INCOME (EXPENSE)     11,961       (21,655 )     12,892       33,666  
                                 
INCOME(LOSS)  BEFORE PROVISION FOR INCOME TAXES     352,100       (1,077,468 )     (285,277 )     (3,281,399 )
                                 
PROVISION FOR INCOME TAXES    
-
     
-
      -       -  
NET INCOME (LOSS)   $ 352,100     $ (1,077,468 )   $ (285,277 )   $ (3,281,399 )
                                 
WEIGHTED AVERGE SHARES OUTSTANDING                                
BASIC     17,347,096       14,667,216       16,720,114       14,638,359  
DILUTED     18,104,807       14,667,216       16,720,114       14,638,359  
                                 
EARNINGS (LOSS) PER SHARE                                
BASIC   $ 0.02     $ (0.07 )   $ (0.02 )   $ (0.22 )
DILUTED   $ 0.02     $ (0.07 )   $ (0.02 )   $ (0.22 )

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3

 

 

OPTIMIZERx CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021

(UNAUDITED)

 

                Additional              
    Common Stock     Paid in     Accumulated        
    Shares     Amount     Capital     Deficit     Total  
                               
Balance January 1, 2021     15,223,340     $ 15,223     $ 85,590,428     $ (35,631,737 )   $ 49,973,914  
                                         
Public offering of common shares, net of offering costs     1,523,750       1,524       70,670,012      
 
      70,671,536  
Shares issued as board compensation     2,695       3       124,991      
-
      124,994  
Shares issued for stock options exercised     510,803       511       1,119,500      
-
      1,120,011  
Stock-based compensation expense     -      
-
      582,159      
-
      582,159  
Net loss     -      
-
     
-
      (637,377 )     (637,377 )
                                         
 Balance March 31, 2021     17,260,588       17,261       158,087,090       (36,269,114 )     121,835,237  
                                         
Shares issued as board compensation     2,035       2       125,089      
-
      125,091  
Shares issued for stock options exercised     232,806       232       1,590,535      
-
      1,590,767  
Stock-based compensation expense     -      
-
      771,947      
-
      771,947  
Net income     -      
-
     
-
      352,100       352,100  
                                         
Balance June 30, 2021     17,495,429     $ 17,495     $ 160,574,661     $ (35,917,014 )   $ 124,675,142  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4

 

 

OPTIMIZERx CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2020

(UNAUDITED)

 

                Additional              
    Common Stock     Paid in     Accumulated        
    Shares     Amount     Capital     Deficit     Total  
                               
Balance January 1, 2020     14,600,579     $ 14,601     $ 78,272,268     $ (33,424,610 )   $ 44,862,259  
                                         
Shares issued as board compensation     11,136       11       99,989      
-
      100,000  
Shares issued for stock options exercised     35,032       35       112,117      
-
      112,152  
Stock-based compensation expense     -      
-
      754,512      
-
      754,512  
Net loss     -      
-
     
-
      (2,203,931 )     (2,203,931 )
                                         
 Balance March 31, 2020     14,646,747       14,647       79,238,886       (35,628,541 )     43,624,992  
                                         
Shares issued as board compensation     7,748       8       100,019      
-
      100,027  
Shares issued for stock options exercised     55,731       56       174,775      
-
      174,831  
Stock-based compensation expense     42,374       42       680,602      
-
      680,644  
Net loss     -      
-
     
-
      (1,077,468 )     (1,077,468 )
                                         
Balance June 30, 2020     14,752,600     $ 14,753     $ 80,194,282     $ (36,706,009 )   $ 43,503,026  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5

 

 

OPTIMIZERx CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

    For the Six Months
Ended
June 30,
 
    2021     2020  
CASH FLOWS FROM OPERATING ACTIVITIES:            
Net Loss   $ (285,277 )   $ (3,281,399 )
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:                
Depreciation, amortization, and non-cash lease expense     1,054,138       1,040,463  
Stock-based compensation     1,354,106       1,435,156  
Stock issued for board services     250,085       200,027  
Provision for loss on accounts receivable     40,000       40,000  
Change in fair value of contingent consideration    
-
      30,000  
Changes in:                
Accounts receivable     (88,221 )    
(3.427,166
)
Prepaid expenses and other assets     1,332,132       (1,785,422 )
Accounts payable     187,211       3,747  
Revenue share payable     (1,628,556 )     1,878,051  
Accrued expenses and other liabilities     (393,778 )     186,682  
Deferred revenue     33,814       68,678  
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES     1,855,654       (3,611,183 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES:                
Purchase of equipment     (43,654 )     (24,998 )
Purchase of intangible assets     (176,822 )    
-
 
NET CASH USED IN INVESTING ACTIVITIES     (220,476 )     (24,998 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:                
    Proceeds from public offering of common stock, net of commission costs     70,671,536      
-
 
    Proceeds from the exercise of options     2,710,778       286,983  
    Payment of contingent consideration     (1,610,813 )     (1,389,188 )
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES     71,771,501       (1,102,205 )
NET INCREASE IN CASH AND CASH EQUIVALENTS     73,406,679       (4,738,386 )
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD     10,516,776       18,852,680  
CASH AND CASH EQUIVALENTS - END OF PERIOD   $ 83,923,455     $ 14,114,294  
                 
SUPPLEMENTAL CASH FLOW INFORMATION:                
Cash paid for interest   $
-
    $
-
 
Cash paid for income taxes   $
-
    $
-
 
Lease liabilities arising from right of use assets   $
-
    $
-
 

 

The accompanying notes are an integral part of these condensed consolidated financial statements. 

 

6

 

 

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2021

 

NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION

 

The accompanying condensed consolidated financial statements include OptimizeRx Corporation and its wholly owned subsidiaries (collectively, the “Company”, “we”, “our”, or “us”).

 

We are a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.

 

The condensed consolidated financial statements for the three and six months ended June 30, 2021 and 2020 are unaudited and have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments necessary to present fairly our consolidated financial position as of June 30, 2021, and our results of operations, changes in stockholders’ equity for the three and six months ended June 30, 2021 and 2020 and the statements of cash flows for the six months ended June 30, 2021 and 2020 have been made. Those adjustments consist of normal and recurring adjustments. The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated balance sheet as of that date.

 

Certain information and note disclosures, including a detailed discussion about the Company’s significant accounting policies, normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated condensed financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the U.S. Securities and Exchange Commission on March 8, 2021.

 

The results of operations for the three and six months ended June 30, 2021, are not necessarily indicative of the results to be expected for the full year.

 

NOTE 2 – NEW ACCOUNTING STANDARDS

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to improve consistent application and simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance. ASU 2019-12 is effective for annual and interim reporting periods beginning after December 12, 2020, with early adoption permitted. The Company adopted this standard effective January 1, 2021. The adoption of this standard did not have a material effect on our financial position, results of operations, or cash flows.

 

NOTE 3 – REVENUES

 

Under ASC 606, Revenue from Contracts with Customers, we record revenue when earned, rather than when billed. From time to time, we may record revenue based on our revenue recognition policies in advance of being able to invoice the customer, or we may invoice the customer prior to being able to recognize the revenue. Included in accounts receivable are unbilled amounts of $1,215,703 and $77,516 at June 30, 2021, and December 31, 2020, respectively. Amounts billed in advance of revenue recognition are presented as deferred revenue on the condensed consolidated balance sheets.

 

7

 

 

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2021

 

NOTE 3 – REVENUES (continued)

 

The majority of our revenue is earned from life sciences companies, such as pharmaceutical and biotech companies, or medical device makers. A small portion of our revenue is earned from other sources, such as associations and technology companies. A break down is set forth in the table below.

 

    Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2021     2020     2021     2020  
Revenue from:                        
Life Science Companies   $ 13,313,044     $ 8,336,298     $ 24,256,404     $ 15,568,032  
Other     312,595       446,932       598,446       799,800  
Total Revenue   $ 13,625,639     $ 8,783,230     $ 24,854,850     $ 16,367,832  

 

NOTE 4 – LEASES

 

We have operating leases for office space in three multitenant facilities with lease terms greater than 12 months, which are recorded as assets and liabilities on our condensed consolidated balance sheets. These leases include our corporate headquarters, located in Rochester, Michigan, a customer service facility in Cranbury, New Jersey, and a technical facility in Zagreb, Croatia. Certain leases contain renewal options and, for the headquarters lease, we have assumed renewal. Lease-related assets, or right-of-use assets, are recognized at the lease commencement date at amounts equal to the respective lease liabilities, adjusted for prepaid lease payments, initial direct costs, and lease incentives received. Lease-related liabilities are recognized at the present value of the remaining contractual fixed lease payments, discounted using our incremental borrowing rate. Amortization of the right of use assets is recognized as non-cash lease expense on a straight-line basis over the lease term, while variable lease payments are expensed as incurred. Short term lease costs include month to month leases in shared office space facilities, such as WeWork, or similar locations.

 

For the three and six months ended June 30, 2021, the Company’s lease cost consisted of the following components, each of which is included in operating expenses within the Company’s condensed consolidated statements of operations:

 

8

 

 

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2021

 

NOTE 4 – LEASES (continued)

 

    Three Months
Ended
June 30,
2021
    Six Months
Ended
June 30,
2021
 
             
Operating lease cost   $ 33,365     $ 66,730  
Short-term lease cost (1)     16,890       32,814  
Total lease cost   $ 50,255     $ 99,544  

 

(1) Short-term lease cost includes any lease with a term of less than 12 months.

 

For the three and six months ended June 30, 2020, the Company’s lease cost consisted of the following components, each of which is included in operating expenses within the Company’s condensed consolidated statements of operations:

 

    Three Months
Ended
June 30,
2020
    Six Months
Ended
June 30,
2020
 
             
Operating lease cost   $ 32,814     $ 65,627  
Short-term lease cost (1)     36,186       80,815  
Total lease cost   $ 69,000     $ 146,442  

 

(1) Short-term lease cost includes any lease with a term of less than 12 months.

 

The table below presents the future minimum lease payments to be made under operating leases as of June 30, 2021:

 

As of June 30, 2021      
       
2021(a)   $ 71,176  
2022     104,572  
2023     101,414  
2024     80,742  
2025     70,224  
Total     428,128  
Less: imputed interest     34,923  
Total lease liabilities   $ 393,205  

 

(a) For the six-month period beginning July 1, 2021.

 

9

 

  

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2021

 

NOTE 4 – LEASES (continued)

 

The weighted average remaining lease term at June 30, 2021 for operating leases was 3.93 years and the weighted average discount rate used in calculating the operating lease asset and liability was 4.5%. Cash paid for amounts included in the measurement of lease liabilities was $62,069 and $57,019 for the six months ended June 30, 2021 and 2020, respectively. For the six months ended June 30, 2021 and 2020, payments on lease obligations were $71,397 and $68,900, respectively, and amortization on the right of use assets was $60,013 and $56,357, respectively.

 

NOTE 5 – STOCKHOLDERS’ EQUITY

 

During the quarter ended March 31, 2021, in an underwritten primary offering, we issued 1,523,750 shares of our common stock for gross proceeds of $75,425,625. In connection with this transaction, we incurred equity issuance costs of $4,754,089 related to payments to the underwriter, advisors and legal fees associated with the transaction, resulting in net proceeds to the Company of $70,671,536.

 

During the quarters ended June 30, 2021 and March 31, 2021, we issued 232,806 shares and 510,803 shares of our common stock, respectively, and received proceeds of $1,590,767 and $1,120,011, respectively, in connection with the exercise of stock options under our 2013 equity incentive plan. Of the shares issued in the quarter ended March 31, 2021, a total of 368,329 shares were issued in a cashless transaction related to 394,739 expiring options using the net settled method whereby 26,410 options were used to pay the purchase price. The remaining 116,064 shares issued in connection with the exercise of options were all issued for cash.

 

During the quarters ended June 30, 2020, and March 31, 2020 we issued 55,731 shares and 35,032 shares of our common stock, respectively, and received proceeds of $174,831 and $112,152, respectively, in connection with the exercise of stock options under our 2013 equity compensation plan.

 

We also issued 42,374 shares in the six months ended June 30, 2020 in connection with restricted stock awards as described in more detail in Note 6 – Stock Based Compensation.

 

Our Director Compensation Plan calls for issuance of shares of common stock each quarter to each independent director. In 2021, we issued 2,695 shares valued at $124,994 in the quarter ended March 31, 2021 and 2,035 shares valued at $125,091 in the quarter ended June 30, 2021. In 2020, we issued 11,136 shares valued at $100,000 in the quarter ended March 31, 2020, and 7,748 shares valued at $100,027 in the quarter ended June 30, 2020.

 

NOTE 6 – STOCK BASED COMPENSATION

 

We use the fair value method to account for stock-based compensation. We recorded $954,434 and $1,021,787 in compensation expense in the six months ended June 30, 2021 and 2020, respectively, related to options issued under our 2013 equity incentive plan. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current period as well as options issued in the current period. The fair value of these instruments was calculated using the Black-Scholes option pricing model. There is $6,183,249 of remaining expense related to unvested options to be recognized in the future over a weighted average remaining period of approximately 2.5 years. The total intrinsic value of outstanding options at June 30, 2021 was $44,669,554.

 

10

 

 

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2021

 

NOTE 6 – STOCK BASED COMPENSATION (continued)

 

In addition to the grants to independent Directors described in Note 5 – Stockholders’ Equity, we also recorded $399,672 and $413,369 in compensation expense related to restricted stock awards that vest over time in the six months ended June 30, 2021, and 2020, respectively. There is $2,588,851 of remaining expense related to unvested restricted stock awards to be recognized in the future over a weighted average period of 3.4 years. A total of 42,374 shares related to restricted stock awards that vested in the six months ended June 30, 2020 and were issued during that same period.

 

NOTE 7 – EARNINGS (LOSS) PER SHARE

 

Basic earnings per share (“EPS”) is computed by dividing net income (loss) by the weighted average number of common shares during the period.

 

The number of shares related to options, restricted stock and other similar instruments included in diluted EPS is based on the “Treasury Stock Method” prescribed in ASC 260-10, Earnings per Share. This method assumes the theoretical repurchase of shares using proceeds of the respective stock option exercised, and for restricted stock, the amount of compensation cost attributed to future services which have not yet been recognized, and the amount of current and deferred tax benefit, if any, that would be credited to additional paid in capital upon the vesting of the restricted stock, at a price equal to the issuer’s average stock price during the related earnings period. Accordingly, the number of shares includable in the calculation of EPS in respect of the stock options, restricted stock and similar instruments is dependent on this average stock price and will increase as the average stock price increases.

 

The following table sets forth the computation of basic and diluted earnings (loss) per share.

 

    Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2021     2020     2021     2020  
Numerator                        
Net income (loss)   $ 352,100     $ (1,077,468 )   $ (285,277 )   $ (3,281,399 )
                                 
Denominator                                
Weighted average shares outstanding used in computing earnings per share                                
Basic     17,347,096       14,667,216       16,720,114       14,638,359  
Effect of dilutive stock options, warrants, and unvested restricted stock awards     757,711      
-
     
-
     
-
 
Diluted     18,104,807       14,667,216       16,720,114       14,638,359  
                                 
Earnings (loss) per share                                
Basic   $ 0.02     $ (0.07 )   $ (0.02 )   $ (0.22 )
Diluted   $ 0.02     $ (0.07 )   $ (0.02 )   $ (0.22 )

 

No calculation of diluted earnings per share is included for either 2020 period or for the six months ended June 30, 2021, as the effect of the calculation would be antidilutive.

 

11

 

 

OPTIMIZERx CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2021

 

NOTE 7 – EARNINGS (LOSS) PER SHARE (CONTINUED)

 

The number of common shares potentially issuable upon the exercise of certain options or for unvested restricted stock awards are reflected in the table below.

 

    Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2021     2020     2021     2020  
                         
Weighted average number of shares excluded from calculation                                
Unvested restricted stock awards     98,011       79,264       94,942       48,027  
Options     659,700       826,777       652,103       782,575  
Total     757,711       906,041       747,045       830,602  

 

NOTE 8 – CONTINGENCIES

 

Litigation

 

The Company is not currently involved in any legal proceedings.

 

NOTE 9 – SUBSEQUENT EVENTS

 

In July 2021, we received proceeds of $300,548 and issued 123,178 shares of common stock in conjunction with the exercise of stock options.

 

In accordance with ASC 855-10, we have analyzed events and transactions that occurred subsequent to June 30, 2021 through the date these financial statements were issued and have determined that we do not have any other material subsequent events to disclose or recognize in these financial statements.

 

12

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.   These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.  We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions.  Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.  Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.  We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

 

Overview

 

COVID-19

 

The full extent of the impact of the COVID-19 pandemic on our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict at the present time. In an effort to contain COVID-19 or slow its spread, governments around the world have enacted various measures, including orders to close all businesses not deemed “essential,” isolate residents to their homes or places of residence, and practice social distancing when engaging in essential activities. We anticipate that these actions and the global health crisis caused by COVID-19 will negatively impact business activity across the globe. While we have not observed any noticeable impact on our revenue related to these conditions in the recently completed fiscal year or quarter, or through the date of this filing, we cannot estimate the impact COVID-19 will have in the future if business and consumer activity decelerates across the globe.

 

In March 2020, we enacted precautionary measures to protect the health and safety of our employees and partners. These measures include closing all offices, having employees work from home, and eliminating virtually all travel. While having employees work from home may have a negative impact on efficiency and may result in negligible increases in costs, it does not impact our ability to execute on our contracts or deliver our core services. We opened our offices on a voluntary basis in June 2021 and we relaxed certain travel restrictions at the same time. Our customers provide essential services in the healthcare industry and we believe that our digital communication technology is more important than ever in this environment. However, our revenue often comes from advertising or marketing budgets, and in a sustained economic downturn, those categories of spending may be cut.

 

We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state, local or foreign authorities, or that we determine are in the best interests of our employees, customers, partners and stockholders. It is not clear what the potential effects any such alterations or modifications may have on our business, including the effects on our customers, partners, or vendors, or on our financial results.

 

13

 

 

Company Highlights through July 2021

 

1. Generated sales of $13.6 million for the quarter ended June 30, 2021, a 55% increase over the same period in 2020.
2. Generated sales of $24.9 million for the six months ended June 30, 2021, a 52% increase over the same period in 2020.
3. Achieved positive cash flow from operations of $1.9 million for the six months ended June 30, 2021.
4. Launched our new Real World Evidence (“RWE”) messaging solution and generated revenue in Q2 from two leading brands.
5. Raised an additional $70.7 million of capital in a public offering.
6. Enhanced our leadership team by adding a General Counsel and Chief Compliance Officer as well as elevated the Chief Technology Officer to report directly to the CEO.
7. Committed to an inclusion and diversity pledge.
8. Enhanced our patient engagement commercial team to further scale that portion of the business.
  Consolidated our technology centers of excellence in Zagreb, Croatia.
9. Completed all integration work for previous two acquisitions and paid last earnout payment related to acquisitions.
10. Maintained a no travel, virtual operational plan with a particular focus on training, open communication, and great work culture.

 

Results of Operations for the Three and Six Months Ended June 30, 2021 and 2020

 

Revenues

 

Our total revenue reported for the three months ended June 30, 2021 was approximately $13.6 million, an increase of 55% over the approximately $8.8 million from the same period in 2020. Our total revenue for the six months ended June 30, 2021 was approximately $24.9 million, an increase of 52% over the approximately $16.4 million from the same period in 2020. The increased revenue resulted from increases in sales in all our messaging products.

 

Cost of Revenues

 

Our cost of revenue percentage, comprised primarily of revenue share expense, decreased slightly as a percentage of revenue in the quarter ended June 30, 2021, as compared to the same period in 2020, while for the six month period ended June 30, 2021, it increased as a percentage of revenue. These changes were the result of solution mix, both as it relates to solutions itself and the partners through which the solutions are delivered. Additional discussion is included in the gross margin section below.

 

    Three Months Ended
June 30
    Six Months Ended
June 30
 
    2021     2020     2021     2020  
                         
Cost of Revenues %     41.0 %     41.4 %     43.0 %     42.0 %
Gross Margin %     59.0 %     58.6 %     57.0 %     58.0 %

 

14

 

 

Gross Margin

 

As reflected in the table above, our gross margin increased slightly in the quarter ended June 30, 2021 compared with the prior year, but decreased slightly for the six month period then ended. This is the result of solution mix. In general, there has been an increase in the percentage of activity flowing through our higher cost channels compared with a year ago. In the second quarter, this was offset by the launch of our RWE solution. Our RWE solution includes a much higher percentage of program design, which carries a higher margin than the delivery of the actual messages. We expect our gross margin to improve on a quarter over quarter basis for the balance of the year as our RWE solution expands and we continue to launch new solutions that have higher margins.

 

Operating Expenses

 

Operating expenses increased from approximately $6.2 million for the three months ended June 30, 2020 to approximately $7.7 million for the same period in 2021. Operating expenses increased from approximately $12.8 million for the six months ended June 30, 2020 to approximately $14.5 million for the same period in 2021. Overall, this increase results from our efforts to expand our product line and build out our organization to establish a strong base for current and future growth. Our expenses increased at a substantially lower rate than our revenues as a result of the operating leverage of our model. The detail of expenditures by major category is reflected in the table below. 

 

    Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2021     2020     2021     2020  
                         
Salaries, Wages, & Benefits   $ 3,906,796     $ 3,176,460     $ 7,487,612     $ 6,382,597  
Stock-Based Compensation     897,038       780,670       1,604,191       1,635,183  
Contractors and Consultants     486,577       560,991       785,963       1,022,236  
Travel     48,925       13,111       58,755       287,622  
Board Compensation     61,250       51,375       122,500       102,750  
Professional Fees     448,598       186,834       769,818       672,304  
Investor Relations     51,019       28,677       97,306       48,127  
Advertising and Promotion     255,680       154,166       384,565       289,068  
Technology Infrastructure Costs     256,291       218,079       469,570       399,791  
Integration and Exclusivity Costs     244,600       207,973       563,158       415,946  
Data Costs     257,484       72,942       545,396       124,554  
Office, Facility, and Other     262,320       227,955       524,480       381,477  
Depreciation and Amortization     527,958       520,794       1,054,138       1,040,463  
                                 
Total Operating Expense   $ 7,704,536     $ 6,200,027     $ 14,467,452     $ 12,802,118  

 

The increase in operating expenses related to salaries, wages, and benefits and other human resource related costs is due to the expansion of our team to support additional growth. This increase is partly offset by the decrease in contractors and consultants, as we have brought functions in house that were previously performed by outsiders.

 

We expect salaries, wages, and benefits to continue to increase on a quarter over quarter basis for the balance of the year due to the full impact of new hires already in place, as well as new hires in the pipeline.

 

Travel expense is down significantly on a year to date basis as a result of travel restrictions due to the pandemic. We expect travel expense to increase significantly starting in the third quarter of the year due to relaxed travel restrictions and pent up demand for meetings and visits.

 

15

 

 

Professional fees increased significantly in the second quarter of 2021 compared with the prior year. With the assistance of an outside legal firm, we undertook a comprehensive governance review of our bylaws, board charters, equity compensation plan, and overall corporate policies. This review resulted in approximately $300,000 of expense in the second quarter. In the six month period ended June 30, 2021, this was partially offset by reduced audit fees as a result of our change in auditors, as well as a change in SEC rules that eliminated the need for a third-party opinion on our internal controls. We would expect professional fees to decrease from the second quarter level for the balance of the year.

 

Investor relations expense increased due to the expansion of our communication efforts to reach retail investors and expand our shareholder base.

 

Technology infrastructure costs increased due to continued investment in our operating systems to facilitate new products as well as the implementation of additional software products to increase efficiency and information dissemination.

 

Data costs increased as we have purchased more data, primarily to aid in our selling effort and allow customers to target their messages more appropriately, thereby increasing our ability to charge premium prices for more highly targeted messages.

 

Integration and exclusivity costs represent payments to partners for access and/or exclusivity and increased because of new agreements signed after the first quarter of 2020. These payments are usually made in lump sums and expensed over the term of the contracts. These expenses are an important part of our ability to expand our network.

 

Our office, facility and other expense increased primarily because of increased activity. The largest single increase related to hiring expenses associated with expanding our team, both for new additions so far, as well as new hires scheduled for the future, including recruiter fees in some instances.

 

All other variances in the table above are the result of normal fluctuations in activity.

 

We expect our overall operating expenses to increase on a quarterly basis for the balance of the year as we further implement our business plan and expand our operations to grow the business in a very dynamic and active marketplace. However, we have established a strong team as a base to support growth and we are seeing the results of the investment in our team last year in our strong revenue growth this year. We do not expect human resource costs to increase as quickly as revenues, however we do expect to continue to add people to accelerate our growth and invest in future growth.

 

Net Income (Loss)

 

We had net income of $0.4 million for the three months ended June 30, 2021, as compared to a net loss of $1.1 million during the same period in 2020. We had a loss of approximately $0.3 million for the six months ended June 30, 2021, as compared to net loss of approximately $3.3 million during the same period in 2020. The reasons and specific components associated with the change are discussed above. Overall, the net income for second quarter of 2021 and decreased loss for the six month period resulted from the increased margin generated by our higher revenues, partially offset by the increased operating expenses.

 

Liquidity and Capital Resources

 

As of June 30, 2021, we had total current assets of $105.0 million, compared with current liabilities of $6.7 million, resulting in working capital of approximately $98.3 million and a current ratio of 15.7 to 1. This represents an increase from our working capital of approximately $23 million and current ratio of 3 to 1 at December 31, 2020.

 

Our operating activities provided approximately $1.9 in cash flow during the six months ended June 30, 2021, compared with cash used of approximately $3.6 million in the same period in 2020. The cash provided in the 2021 period was the result of our net loss increased by noncash expenses, partially offset by working capital used in the reduction of liabilities. The cash used in the 2020 period was primarily the result of increased investment in working capital; in particular, we made a $2.0 million prepayment to a partner that was expensed over the balance of the year.

 

16

 

 

We used insignificant amounts in investing activities in both the six months ended June 30, 2021 and 2020. These investments related to purchases of equipment as well as investments related to the expansion of our network capabilities in our patient engagement solution. 

 

Our financing activities provided $71.8 million in the six months ended June 30, 2021, compared with cash used of approximately $1.1 million in the same period in 2020. We raised $70.7 million in a public offering of our common stock as well as generated $2.7 million from the issuance of shares related to the exercise of stock options. These were partially offset by the payment of $1.6 in earnout payments from a previous acquisition. We have no remaining earnout payments due in the future. Financing activities used approximately $1.3 million related to earnout payments from a previous acquisition, offset by $0.3 million from the issuance of shares related to the exercise of stock options.

 

We do not anticipate the need to raise additional capital in the short or long term for operating purposes or to fund our growth plans. We are focused on growing our revenue, channel and partner network. However, as a company in a market that is active with merger and acquisition activity, we may have opportunities, such as for acquisitions or strategic partner relationships, which may require additional capital. We will assess these opportunities as they arise with the view of maximizing shareholder value.

 

Critical Accounting Policies

 

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our accounting policies are discussed in the footnotes to our financial statements included in our annual report on Form 10-K for the year ended December 31, 2020; however, we consider our critical accounting policies to be those related to determining the amount of revenue to be billed, the timing of revenue recognition, calculation of revenue share expense, stock-based compensation, capitalization and related amortization of intangible assets, impairment of assets, and the fair value of liabilities.  

 

Recently Issued Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to improve consistent application and simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance. ASU 2019-12 was effective for annual and interim reporting periods beginning after December 12, 2020, with early adoption permitted. The adoption of this standard did not have a material effect on our financial position, results of operations, or cash flows.

 

Off Balance Sheet Arrangements

 

As of June 30, 2021, there were no off-balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

We are not required to provide the information required by this Item.

 

17

 

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this report (the “Evaluation Date”). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded as of the Evaluation Date that our disclosure controls and procedures were effective such that the material information required to be included in our SEC reports is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms relating to our company, including, our consolidated subsidiaries, and was made known to them by others within those entities, particularly during the period when this report was being prepared.

  

Changes in Internal Control over Financial Reporting

 

During the quarter ended June 30, 2021, we made routine ongoing improvements in our internal control and processes and hired an additional finance department team member, however, no material changes were made during the period.

 

Limitations on the Effectiveness of Controls

 

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

18

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not a party to any material pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

Item 1A: Risk Factors

 

See risk factors included in our Annual Report on Form 10-K for 2020.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

During the quarter ended June 30, 2021, we issued 2,035 shares of restricted common stock to our independent directors in connection with our Director Compensation Plan. We also issued a total 232,806 shares of stock in connection with the exercise of options.

 

In July 2021, we issued 123,178 shares of common stock in conjunction with the exercise of stock options.

 

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

 

19

 

 

Item 3. Defaults upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosure

 

N/A

 

Item 5. Other Information

 

None 

 

Item 6. Exhibits

 

Exhibit 
Number
  Description of Exhibit
10.1**   Addendum to the employment agreement between William Febbo and the Company dated September 24, 2020
31.1**   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2**   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

  

  ** Provided herewith

 

20

 

 

SIGNATURES

 

In accordance with the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  OptimizeRx Corporation
Date: August 4, 2021    
  By: /s/ William J. Febbo
    William J. Febbo
  Title:    Chief Executive Officer,
Principal Executive Officer, and Director

 

  OptimizeRx Corporation
Date: August 4, 2021    
  By: /s/ Douglas P. Baker
    Douglas P. Baker
  Title:   Chief Financial Officer,
Principal Financial Officer and
Principal Accounting Officer

 

 

21

 

3.427166 false 248 --12-31 Q2 2021 0001448431 OptimizeRx Corp 651-6568 0001448431 2021-01-01 2021-06-30 0001448431 2021-07-30 0001448431 2021-06-30 0001448431 2020-12-31 0001448431 2021-04-01 2021-06-30 0001448431 2020-04-01 2020-06-30 0001448431 2020-01-01 2020-06-30 0001448431 us-gaap:CommonStockMember 2020-12-31 0001448431 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001448431 us-gaap:RetainedEarningsMember 2020-12-31 0001448431 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001448431 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001448431 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001448431 2021-01-01 2021-03-31 0001448431 us-gaap:CommonStockMember 2021-03-31 0001448431 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001448431 us-gaap:RetainedEarningsMember 2021-03-31 0001448431 2021-03-31 0001448431 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001448431 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001448431 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001448431 us-gaap:CommonStockMember 2021-06-30 0001448431 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001448431 us-gaap:RetainedEarningsMember 2021-06-30 0001448431 us-gaap:CommonStockMember 2019-12-31 0001448431 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001448431 us-gaap:RetainedEarningsMember 2019-12-31 0001448431 2019-12-31 0001448431 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001448431 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001448431 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001448431 2020-01-01 2020-03-31 0001448431 us-gaap:CommonStockMember 2020-03-31 0001448431 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001448431 us-gaap:RetainedEarningsMember 2020-03-31 0001448431 2020-03-31 0001448431 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001448431 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001448431 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001448431 us-gaap:CommonStockMember 2020-06-30 0001448431 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001448431 us-gaap:RetainedEarningsMember 2020-06-30 0001448431 2020-06-30 0001448431 oprx:LifeScienceCompaniesMember 2021-04-01 2021-06-30 0001448431 oprx:LifeScienceCompaniesMember 2020-04-01 2020-06-30 0001448431 oprx:LifeScienceCompaniesMember 2021-01-01 2021-06-30 0001448431 oprx:LifeScienceCompaniesMember 2020-01-01 2020-06-30 0001448431 oprx:OtherMember 2021-04-01 2021-06-30 0001448431 oprx:OtherMember 2020-04-01 2020-06-30 0001448431 oprx:OtherMember 2021-01-01 2021-06-30 0001448431 oprx:OtherMember 2020-01-01 2020-06-30 0001448431 oprx:PrivateTransactionMember 2021-01-01 2021-03-31 0001448431 oprx:LegalFeesMember 2021-01-01 2021-03-31 0001448431 oprx:RMDYHealthIncMember 2021-03-31 0001448431 oprx:RMDYHealthIncMember 2021-01-01 2021-06-30 0001448431 oprx:RMDYHealthIncMember 2021-01-01 2021-03-31 0001448431 srt:DirectorMember 2021-03-31 0001448431 srt:DirectorMember 2021-01-01 2021-03-31 0001448431 srt:DirectorMember 2021-06-30 0001448431 srt:DirectorMember 2021-01-01 2021-06-30 0001448431 srt:DirectorMember 2020-03-31 0001448431 srt:DirectorMember 2020-01-01 2020-03-31 0001448431 srt:DirectorMember 2020-06-30 0001448431 srt:DirectorMember 2020-01-01 2020-06-30 0001448431 us-gaap:StockCompensationPlanMember 2021-01-01 2021-06-30 0001448431 us-gaap:StockCompensationPlanMember 2020-01-01 2020-06-30 0001448431 us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001448431 us-gaap:RestrictedStockMember 2020-01-01 2020-06-30 0001448431 us-gaap:SubsequentEventMember 2021-07-01 2021-07-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Exhibit 10.1

 

Employment Agreement Addendum 2

Addendum to agreement dated February 25, 2019

 

This second addendum to the employment agreement (the “Addendum”) is made this 24th day of September 2020, by and between OptimizeRx, Corporation (the “Company”), a Nevada Company, and William Febbo (the “Executive”).

 

Severance

 

The following paragraph is hereby deleted in its entirety and replaced as indicated below.

 

If (i) your employment is terminated by us without Cause (as defined below), (ii) you resign following an event constituting Good Reason (as defined below), provided that you have given written notice to the Company of such event within forty-five (45) days of its occurrence and the Company has failed to cure such event within thirty (30) days following receipt of such notice, or (iii) you no longer render services to us as a result of your death or Disability (as defined below), then you will receive a severance payment in the amount equal to twelve (12) months of your then applicable base pay, less applicable withholding taxes and regular deductions, payable in a lump sum (“Severance Benefits”). Health benefits will also be provided, at the Company’s sole expense during the applicable severance term.

 

The following paragraph replaces the deleted paragraph:

 

If (i) your employment is terminated by us without Cause (as defined below), (ii) you resign following an event constituting Good Reason (as defined below), provided that you have given written notice to the Company of such event within forty-five (45) days of its occurrence and the Company has failed to cure such event within thirty (30) days following receipt of such notice, or (iii) you no longer render services to us as a result of your death or Disability (as defined below), then you will receive a severance payment in the amount equal to twelve (12) months of your then applicable base pay, less applicable withholding taxes and regular deductions, payable in a lump sum (“Severance Benefits”). You will also receive your annual target bonus based on the rate of base pay in effect at the time. Benefits, including health, dental, vision, life, and disability, as well as company retirement plan contributions, will also be provided, at the Company’s sole expense during the applicable severance term.

 

Change in Control Benefits:

 

The following paragraph is hereby deleted in its entirety and replaced as indicated below

 

In the event of a Change in Control (as defined below) during which you were actively employed, you will receive (i) twelve (12) months of your final base pay rate; and (ii) if the Company’s equity awards are assumed in the Change in Control, accelerated vesting of the number of your then-unvested Company stock option shares it being acknowledge and agreed that this section shall supersede any language to the contrary in any other document including the Form of Option Grant Agreement (collectively, the “Change in Control Benefits”). The Change in Control Benefits would be provided in lieu of any other severance-related benefits for which you may be eligible.

 

The following paragraph replaces the deleted paragraph:

 

In the event of a Change in Control (as defined below) during which you were actively employed, you will receive (i) eighteen (18) months of your final base pay rate; and (ii) an amount equal to your target bonus associated with such final base pay based, calculated as 1.5 times the annual target amount: and (iii) eighteen months of company provided benefits including health, dental, vision, life, and disability insurance, as well as company retirement plan contributions;’ and (iv) if the Company’s equity awards are assumed in the Change in Control, accelerated vesting of the number of your then-unvested Company stock option shares it being acknowledge and agreed that this section shall supersede any language to the contrary in any other document including the Form of Option Grant Agreement (collectively, the “Change in Control Benefits”). The Change in Control Benefits would be provided in lieu of any other severance-related benefits for which you may be eligible.

 

Effective Date: September 24, 2020

 

Acknowledgment:

Except as expressly set forth herein, all other terms of the Agreement remain in full force and effect.

 

OptimizeRx, Corporation William Febbo

 

By: /s/ Douglas P Baker   By:

/s/ William Febbo

Its: Chief Financial Officer   Date: September 24, 2020
Date: September 24, 2020      

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, William J. Febbo, certify that;

 

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2021 of OptimizeRx Corp (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 4, 2021  
   
/s/ William J. Febbo  
By: William J. Febbo  
Title: Chief Executive Officer  

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Douglas P. Baker, certify that;

 

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2021 of OptimizeRx Corp (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 4, 2021  
   
/s/ Douglas P. Baker  
By: Douglas P. Baker  
Title: Chief Financial Officer  

 

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly Report of OptimizeRx Corp (the “Company”) on Form 10-Q for the quarter ended June 30, 2021 filed with the Securities and Exchange Commission (the “Report”), I, Will Febbo, Chief Executive Officer and I, Douglas Baker, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

 

By: /s/ William J Febbo  
Name:  Willian J Febbo  
Title: Principal Executive Officer, and Director  
Date: August 4, 2021  
     
By: /s/ Douglas P. Baker  
Name:  Douglas P. Baker  
Title: Principal Financial Officer  
Date: August 4, 2021  

 

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.